Restricted accessResearch articleFirst published online 2018-07
Response to Paricio-Talayero and Baeza re: “Oral Administration to Nursing Women of Lactobacillus fermentum CECT5716 Prevents Lactational Mastitis Development: A Randomized Controlled Trial”
Paricio-TalayeroJM, BaezaC. Re: “Oral administration to nursing women of Lactobacillus fermentum CECT5716 prevents lactational mastitis development: A randomized controlled trial” by Hurtado et al. (Breastfeed Med 2017;12:202–209). Breastfeed Med, 2018; 13:453–454.
2.
HurtadoJA, Maldonado-LoboJA, Díaz-RoperoMP, et al.Oral administration to nursing women of Lactobacillus fermentum CECT5716 prevents lactational mastitis development: A randomized controlled trial. Breastfeed Med, 2017; 12:202–209.
3.
MedianoP, FernándezL, RodríguezJM, et al.Case-control study of risk factors for infectious mastitis in Spanish breastfeeding women. BMC Pregnancy Childbirth, 2014; 14:195.
4.
Martínez de TejadaB.Antibiotic use and misuse during pregnancy and delivery: Benefits and risks. Int J Environ Res Public Health, 2014; 11:7993–8009.
5.
Fernández-CañadasA, DuránM, Hernández-LópezA, et al.A comparison of factors associated with cessation of exclusive breastfeeding at 3 and 6 months. Breastfeed Med, 2017; 12:430435.
World Health Organization. Mastitis: Causes and management. Geneva, Switzerland: World Health Organization, 2000.
8.
ArroyoR, MartínV, MaldonadoA, et al.Treatment of infectious mastitis during lactation: Antibiotics versus oral administration of Lactobacilli isolated from breast milk. Clin Infect Dis, 2010; 50:1551–1558.
9.
DelgadoS, ArroyoR, JiménezE, et al.Staphylococcus epidermidis strains isolated from breast milk of women suffering infectious mastitis: Potential virulence traits and resistance to antibiotics. BMC Microbiol, 2009; 9:82.
